| The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo … C Baigent, MJ Landray, C Reith, J Emberson, DC Wheeler, C Tomson, ... The Lancet 377 (9784), 2181-2192, 2011 | 2929 | 2011 |
| The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo … C Baigent, MJ Landray, C Reith, J Emberson, DC Wheeler, C Tomson, ... The Lancet 377 (9784), 2181-2192, 2011 | 2929 | 2011 |
| Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease W Herrington, B Lacey, P Sherliker, J Armitage, S Lewington Circulation research 118 (4), 535-546, 2016 | 1374 | 2016 |
| Empagliflozin in patients with chronic kidney disease EMPA-Kidney Collaborative Group New England Journal of Medicine 388 (2), 117-127, 2023 | 794 | 2023 |
| Association between diabetes and cause-specific mortality in rural and urban areas of China F Bragg, MV Holmes, A Iona, Y Guo, H Du, Y Chen, Z Bian, L Yang, ... Jama 317 (3), 280-289, 2017 | 491 | 2017 |
| Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease Sharp Collaborative Group American heart journal 160 (5), 785-794. e10, 2010 | 410 | 2010 |
| Diabetes and cause-specific mortality in Mexico City J Alegre-Díaz, W Herrington, M López-Cervantes, L Gnatiuc, R Ramirez, ... New England Journal of Medicine 375 (20), 1961-1971, 2016 | 314 | 2016 |
| The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study WG Herrington, D Preiss, R Haynes, M von Eynatten, N Staplin, ... Clinical kidney journal 11 (6), 749-761, 2018 | 248 | 2018 |
| Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomized double-blind trial R Haynes, PK Judge, N Staplin, WG Herrington, BC Storey, A Bethel, ... Circulation 138 (15), 1505-1514, 2018 | 203 | 2018 |
| Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials W Herrington, J Emberson, B Mihaylova, L Blackwell, C Reith, R Haynes, ... Lancet Diabetes and Endocrinology 4 (10), 2016 | 200 | 2016 |
| Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies L Gnatiuc, WG Herrington, J Halsey, J Tuomilehto, X Fang, HC Kim, ... The lancet Diabetes & endocrinology 6 (7), 538-546, 2018 | 198 | 2018 |
| Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials C Baigent, JR Emberson, R Haynes, WG Herrington, P Judge, ... The Lancet 400 (10365), 1788-1801, 2022 | 192 | 2022 |
| 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients … N Marx, M Federici, K Schütt, D Müller-Wieland, RA Ajjan, MJ Antunes, ... European heart journal 44 (39), 4043-4140, 2023 | 191 | 2023 |
| Effects of lowering LDL cholesterol on progression of kidney disease R Haynes, D Lewis, J Emberson, C Reith, L Agodoa, A Cass, JC Craig, ... Journal of the American Society of Nephrology 25 (8), 1825-1833, 2014 | 191 | 2014 |
| KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease PE Stevens, SB Ahmed, JJ Carrero, B Foster, A Francis, RK Hall, ... Kidney international 105 (4), S117-S314, 2024 | 169 | 2024 |
| Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis A Marthi, K Donovan, R Haynes, DC Wheeler, C Baigent, CM Rooney, ... Journal of the American Society of Nephrology 29 (7), 2015-2027, 2018 | 162 | 2018 |
| Metformin: the safest hypoglycaemic agent in chronic kidney disease? HJ Nye, WG Herrington Nephron Clinical Practice 118 (4), c380-c383, 2011 | 147 | 2011 |
| Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference C Baigent, WG Herrington, J Coresh, MJ Landray, A Levin, V Perkovic, ... Kidney international 92 (2), 297-305, 2017 | 123 | 2017 |
| Body-mass index and risk of advanced chronic kidney disease: Prospective analyses from a primary care cohort of 1.4 million adults in England WG Herrington, M Smith, C Bankhead, K Matsushita, S Stevens, T Holt, ... PloS one 12 (3), e0173515, 2017 | 122 | 2017 |
| Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop A Tong, B Manns, AYM Wang, B Hemmelgarn, DC Wheeler, J Gill, ... Kidney international 94 (6), 1053-1068, 2018 | 119 | 2018 |
Hussein Al-MossawiRheumatology Research Fellow, University of OxfordПідтверджена електронна адреса в ndorms.ox.ac.uk
